CERO TERAPEUTICS HLDG INC (CERO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 12, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CERO SEC filings page.
This page shows CERO TERAPEUTICS HLDG INC (CERO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest balance sheet shows a capital-constrained development business, with liabilities outweighing assets and operating cash use far exceeding its asset base.
In FY2025, operating cash flow was-$16.1M against$3.6M of assets, while the liquidity measure equaled just 1.2 months of reported annual outflow; together, that points to financing needs large relative to current balance-sheet resources. The shift from a 0.5x current ratio in FY2024 to 0.3x in FY2025 shows short-term obligations becoming less covered by current assets, not merely a larger accounting loss.
FY2025 liabilities of
The operating record is incomplete: FY2023 reported revenue of
Financial Health Signals
CERO TERAPEUTICS HLDG INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
CERO TERAPEUTICS HLDG INC's EBITDA was -$3.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 18.5% from the same quarter a year earlier.
CERO TERAPEUTICS HLDG INC reported -$1.0M in net income in Q2 2026. This represents an increase of 81.0% from the same quarter a year earlier. Against the prior quarter it is up 82.5%.
Not reported for Q2 2026.
Cash & Balance Sheet
CERO TERAPEUTICS HLDG INC held $863K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
CERO TERAPEUTICS HLDG INC invested $1.7M in research and development in Q2 2026. This represents a decrease of 37.0% from the same quarter a year earlier. Against the prior quarter it is down 25.8%.
Not reported for Q2 2026.
Not reported for Q2 2026.
CERO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $1.7M-37.0% | $2.3M-19.6% | N/A | $2.4M+34.5% | $2.8M+1.5% | $2.9M+221.7% | N/A | $1.8M+38.9% |
| SG&A Expenses | $2.1M+7.1% | $2.5M+22.7% | N/A | $2.0M-24.8% | $2.0M-19.1% | $2.0M-25.7% | N/A | $2.6M+918.6% |
| Operating Income | -$3.8M+18.6% | -$4.8M+2.1% | N/A | -$4.4M+0.9% | -$4.7M+8.2% | -$5.0M-35.4% | N/A | -$4.4M-186.7% |
| EBITDA | -$3.8M+18.5% | N/A | N/A | -$4.3M-0.1% | -$4.6M+7.7% | -$4.9M-36.2% | N/A | -$4.3M-202.0% |
| Interest Expense | $690K | $166K | N/A | N/A | N/A | N/A | N/A | -$4K-2714.0% |
| Net Income | -$1.0M+81.0% | -$5.9M-15.3% | N/A | -$4.9M-14.9% | -$5.4M-121.2% | -$5.1M-195.6% | N/A | -$4.2M-213.3% |
| EPS (Basic) | -$0.70+98.9% | -$0.20+99.4% | N/A | -$9.10+94.7% | -$61.71+79.6% | -$31.82-160.0% | N/A | -$170.22-113380.0% |
| EPS (Diluted) | -$0.70 | -$0.20 | N/A | -$9.10 | -$61.71 | -$31.82 | N/A | -$170.22 |
| Diluted Shares (Avg) | 42M | 29M | N/A | 1M | 488,076 | 171,381 | N/A | 24,838 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
CERO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.9M-69.4% | $2.2M-72.4% | $3.6M-41.3% | $3.9M-39.8% | $6.2M-15.9% | $8.0M-11.7% | $6.2M+21.1% | $6.5M-23.4% |
| Current Assets | $1.5M-63.5% | $1.6M-72.7% | $2.7M-26.4% | $2.6M-31.2% | $4.2M0.0% | $5.8M+4.8% | $3.7M+88.5% | $3.7M |
| Cash & Equivalents | $863K-73.3% | $857K-83.2% | $1.7M-50.0% | $1.9M-43.8% | $3.2M-11.5% | $5.1M+11.0% | $3.3M+3334.5% | $3.4M+2740.2% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $32.4M+313.5% | $11.5M+37.8% | $9.1M+12.2% | $8.5M-17.1% | $7.8M-20.5% | $8.3M-36.1% | $8.1M-82.8% | $10.2M-54.2% |
| Current Liabilities | $32.4M+325.4% | $11.3M+44.1% | $9.1M+22.8% | $8.5M-10.3% | $7.6M-13.2% | $7.9M-32.5% | $7.4M+111.1% | $9.4M+96.3% |
| Non-Current Liabilities | $0-100.0% | $137K-70.4% | $0-100.0% | $0-100.0% | $218K-79.7% | $462K-66.6% | $699K-98.4% | $772K-95.6% |
| Long-Term Debt | N/A | $137K | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$30.5M-1767.0% | -$9.3M-2710.9% | -$5.4M-187.5% | -$4.5M-22.7% | -$1.6M+34.2% | -$329K+91.7% | -$1.9M+95.5% | -$3.7M+73.1% |
| Retained Earnings | -$97.8M-20.0% | -$96.7M-27.2% | -$90.8M-28.1% | -$86.3M-20.5% | -$81.4M-20.9% | -$76.0M-17.1% | -$70.9M-64.6% | -$71.6M-420.0% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.
CERO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.9M | $2.8M | N/A | N/A | N/A | N/A | N/A | N/A |
| Depreciation & Amortization | $59K-23.3% | N/A | N/A | $69K-39.1% | $76K-33.3% | $76K0.0% | N/A | $114K-1.3% |
| Stock-Based Compensation | $1.1M+512.1% | $1.6M+430.4% | N/A | $348K-13.0% | $183K+511.1% | $305K+238.8% | N/A | $400K |
| Dividends Paid | N/A | $127K0.0% | $0 | $43K | -$43K | $127K | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Share Buybacks.
CERO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$5.4M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.30), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| CERO TERAPEUTICS HLDG INC CERO | FY2025 | N/A | N/A | N/A | $320K | — |
| PharmaCyte Biotech, Inc. PMCB | FY2026 | $0 | -$19.4M | N/A | $4.3M | — |
| Cardio Diagnostics Holdings Inc. CDIO | FY2025 | $15K | -$6.5M | N/A | $5.5M | — |
| Artelo Biosciences, Inc. ARTL | FY2025 | N/A | -$12.9M | N/A | $1.8M | — |
| AIM ImmunoTech Inc. AIM | FY2025 | $88K | -$14.0M | N/A | $7.2M | — |
Where CERO TERAPEUTICS HLDG INC Ranks
Frequently Asked Questions
Does CERO TERAPEUTICS HLDG INC pay dividends?
Yes, CERO TERAPEUTICS HLDG INC (CERO) paid $10.37 per share in dividends during fiscal year 2025.
What is CERO TERAPEUTICS HLDG INC's operating cash flow?
CERO TERAPEUTICS HLDG INC (CERO) recorded an outflow of $16.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are CERO TERAPEUTICS HLDG INC's total assets?
CERO TERAPEUTICS HLDG INC (CERO) had $3.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What is CERO TERAPEUTICS HLDG INC's current ratio?
CERO TERAPEUTICS HLDG INC (CERO) had a current ratio of 0.30 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is CERO TERAPEUTICS HLDG INC's P/E ratio?
CERO TERAPEUTICS HLDG INC (CERO) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $320K as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is CERO TERAPEUTICS HLDG INC's price-to-sales ratio?
CERO TERAPEUTICS HLDG INC (CERO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $320K as of Oct 12, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does CERO TERAPEUTICS HLDG INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, CERO TERAPEUTICS HLDG INC (CERO) held $1.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $16.1M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is CERO TERAPEUTICS HLDG INC's debt-to-equity ratio negative or not reported?
CERO TERAPEUTICS HLDG INC (CERO) has negative shareholder equity of -$5.4M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.